Standard BioTools reported a 3% year-over-year revenue decline in Q2 2025, with notable decreases in instrument and service sales offset somewhat by consumables growth. The company’s net loss narrowed compared to the prior year while continuing investments in restructuring and transformation initiatives. The planned divestment of SomaLogic to Illumina marks a strategic shift focusing on core business areas. Challenges persist with constrained academic spending and capital markets, reflecting broader biotech industry headwinds.